Malignant Peritoneal Neoplasm — Trials

Malignant Peritoneal Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

502 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 124
Recruiting: 53
Ph III recruiting: 7
Growth YoY: —
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: 29.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (75)

clinicaltrialsPublishedShowing 401–450 of 502 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00903630	Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	terminated	Phase 1 / Phase 2	15	Masonic Cancer Center, University of MinnesotaOTHER	1	Dec 28, 2017	clinicaltrials
NCT01145430	Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer	completed	Phase 1	45	National Cancer Institute (NCI)NIH